Neladenoson bialanate

Drug Profile

Neladenoson bialanate

Alternative Names: BAY-1067197

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Heart failure therapies
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure

Most Recent Events

  • 13 Dec 2016 Bayer plans the phase II PANTHEON trial for Chronic heart failure (patients with reduced ejection fraction) in USA, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Japan, Netherlands, Poland and Spain (PO) (NCT02992288)
  • 26 Sep 2016 Chemical structure information added
  • 01 Apr 2015 Bayer completes the phase II PARSiFAL trial in Chronic heart failure in Germany, Italy, Netherlands and Poland (NCT02040233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top